Summary
Sorrento Therapeutics Inc (STI), formerly QuikByte Software Inc is a biopharmaceutical company that develops novel treatments for cancer, inflammation and autoimmune diseases. The company discovers small molecules, antibody drug conjugates, and antibodies for the treatment of cancer and its associated pain. It offers multiple late-stage biosimilar and biobetter antibodies and clinical CAR-T therapies. STI is also developing cell internalizing mAbs against undruggable intracellular targets. The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. STI is headquartered in San Diego, California, the US.
Sorrento Therapeutics Inc (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Sorrento Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 15
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 16
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 17
Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 18
Venture Financing 19
Scilex Pharma Raises USD0.5 Million in Financing 19
Globavir Biosciences Secures USD4 Million in Venture Funding 20
Scilex Pharma Raises US$5 Million In Venture Financing 21
Partnerships 22
Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 22
Sorrento Therapeutics to Form Joint Venture with CHA Biotech 23
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 24
Sorrento Therapeutics to Form Joint Venture with Yuhan 25
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 26
Sorrento Therapeutics and NantBioscience Form Joint Venture 27
Advaxis Enters into Research Agreement with Sorrento Therapeutics 28
Sorrento Therapeutics Enters into Co-Development Agreement with Conkwest 29
NantWorks to Form Joint Venture with Sorrento Therapeutics 30
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 31
Licensing Agreements 32
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 32
Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 33
NantWorks to Enter into Licensing Agreement with Sorrento Therapeutics 34
Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 35
Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 36
Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 37
Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 38
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 39
Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 40
Equity Offering 41
Sorrento Therapeutics to Raise Funds through Public Offering of Shares 41
Sorrento Therapeutics Raises USD47.3 Million in Public Offering of Shares 42
Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 44
Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 45
Sorrento Therapeutics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 47
Scilex Pharma Announces Private Placement Of Shares And Warrants For US$5 Million 49
Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million 50
Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million 52
Sorrento Therapeutics Completes Private Placement Of Shares For US$2 Million 53
Acquisition 54
TNK Therapeutics Acquires Virttu Biologics 54
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 55
Scintilla Pharma to Acquire Semnur Pharma 56
TNK Therapeutics Acquires Two Biotechnology Companies 57
NantPharma Acquires IgDraSol from Sorrento Therapeutics 58
Itochu Chemical Frontier Invests in Scilex Pharma 59
NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 60
Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million 61
Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 62
Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million 63
Sorrento Therapeutics Inc - Key Competitors 65
Sorrento Therapeutics Inc - Key Employees 66
Sorrento Therapeutics Inc - Locations And Subsidiaries 67
Head Office 67
Other Locations & Subsidiaries 67
Joint Venture 68
Recent Developments 69
Strategy And Business Planning 69
May 04, 2017: Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business 69
Corporate Communications 70
Aug 15, 2016: Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development 70
Aug 01, 2016: Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors 71
Apr 05, 2016: Sorrento Appoints Kevin M. Herde As Chief Financial Officer 72
Legal and Regulatory 73
Jun 14, 2017: Sorrento Therapeutics Announces Dismissal Of Lawsuits 73
Product News 74
12/01/2016: Sorrentos TNK Therapeutics Provides Progress Update for its CD123 CAR-T Program for Treatment of Hematological Malignancies 74
Clinical Trials 75
Nov 07, 2016: Phase I/IIa Mesothelioma Study completes dosing of patients and further clinical updates 75
Other Significant Developments 76
May 09, 2016: Sorrento Therapeutics engaged advisors for exploring strategic alternatives 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
List of Tables
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Sorrento Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Sorrento Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 15
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 16
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 17
Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 18
Scilex Pharma Raises USD0.5 Million in Financing 19
Globavir Biosciences Secures USD4 Million in Venture Funding 20
Scilex Pharma Raises US$5 Million In Venture Financing 21
Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 22
Sorrento Therapeutics to Form Joint Venture with CHA Biotech 23
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 24
Sorrento Therapeutics to Form Joint Venture with Yuhan 25
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 26
Sorrento Therapeutics and NantBioscience Form Joint Venture 27
Advaxis Enters into Research Agreement with Sorrento Therapeutics 28
Sorrento Therapeutics Enters into Co-Development Agreement with Conkwest 29
NantWorks to Form Joint Venture with Sorrento Therapeutics 30
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 31
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 32
Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 33
NantWorks to Enter into Licensing Agreement with Sorrento Therapeutics 34
Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 35
Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 36
Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 37
Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 38
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 39
Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 40
Sorrento Therapeutics to Raise Funds through Public Offering of Shares 41
Sorrento Therapeutics Raises USD47.3 Million in Public Offering of Shares 42
Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 44
Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 45
Sorrento Therapeutics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 47
Scilex Pharma Announces Private Placement Of Shares And Warrants For US$5 Million 49
Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million 50
Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million 52
Sorrento Therapeutics Completes Private Placement Of Shares For US$2 Million 53
TNK Therapeutics Acquires Virttu Biologics 54
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 55
Scintilla Pharma to Acquire Semnur Pharma 56
TNK Therapeutics Acquires Two Biotechnology Companies 57
NantPharma Acquires IgDraSol from Sorrento Therapeutics 58
Itochu Chemical Frontier Invests in Scilex Pharma 59
NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 60
Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million 61
Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 62
Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million 63
Sorrento Therapeutics Inc, Key Competitors 65
Sorrento Therapeutics Inc, Key Employees 66
Sorrento Therapeutics Inc, Subsidiaries 67
Sorrento Therapeutics Inc, Joint Venture 68
List of Figures
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Sorrento Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11
